



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 209/82, 403/04, 403/06, 403/12, 473/16, 475/08	A1	(11) International Publication Number: WO 00/59884 (43) International Publication Date: 12 October 2000 (12.10.00)
(21) International Application Number: PCT/US00/01968 (22) International Filing Date: 25 January 2000 (25.01.00) (30) Priority Data: 60/117,321 26 January 1999 (26.01.99) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/117,321 (CIP) Filed on 26 January 1999 (26.01.99) (71) Applicant (for all designated States except US): DANA-FARBER CANCER INSTITUTE, INC. [US/US]; 44 Binney Street, Boston, MA 02115 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): ROSOWSKY, Andre [US/US]; 76 Lindbergh Avenue, Needham, MA 02194 (US). (74) Agents: CORLESS, Peter, F. et al.; Dike, Bronstein, Roberts & Cushman, LLP, 130 Water Street, Boston, MA 02109 (US).		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE THEREOF (57) Abstract The invention relates to pharmaceutically active compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are particularly useful for the treatment or prophylaxis of diseases associated with parasitic infection such as toxoplasmosis, cryptosporidiosis, leishmaniasis and malaria.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE THEREOF

This invention was made with government support under Grant No. RO1A129904 awarded by the National Institutes of Health. The government has certain rights in this invention.

BACKGROUND OF THE INVENTION

5 1. Field of the Invention

The present invention relates to pharmaceutically active compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are particularly useful for the treatment or prophylaxis of diseases associated with parasitic infection, such as
10 toxoplasmosis, cryptosporidiosis, leishmaniasis and malaria.

2. Background

Parasitic-related diseases are highly prevalent and often difficult to treat. For example, toxoplasmosis, caused by the parasitic protozoan *Toxoplasma gondii*, is a leading cause of morbidity and mortality in patients with AIDS as well as in other
15 immunocompromised patients such as persons receiving immunosuppressive cancer chemotherapy. Toxoplasmosis also is suffered by the developing fetus with the potential result of severe neurological damage. The disease is also problematic for livestock and other domesticated animals. For example, toxoplasmosis causes spontaneous abortion in sheep.

20 Pneumocystis pneumonia, cryptosporidiosis, leishmaniasis and malaria also result from parasitic infection and can be difficult to treat, particularly in immunocompromised subjects. Pneumocystis pneumonia results from infection by *Pneumocystis carinii*, a fungal parasite which is benign in immunocomponent

- 2 -

individuals but can be life-threatening in patients with AIDS. Cryptosporidiosis results from infection of protozoa of the genus *Cryptosporidium* and, in the case of immunocompromised individuals, the disease can be chronic and life threatening. Leishmaniasis is any of a group of conditions resulting from *Leishmania* infection.

- 5 Manifestations of leishmaniasis are significantly enhanced in the immunocompromised. Malaria can result from infection of several different parasites: *Plasmodium vivax*, *P. falciparum*, *P. malarie*, and *P. ovale*. See generally *The Merck Manual*, 16th edition.

- 10 Current therapies to treat toxoplasmosis and other parasitic infections have included use of trimethoprim and pyrimethamine. See *Merck Index* 8169 and 9840 (12th edition.). However, these agents are often not sufficiently potent to be fully effective when used alone and, consequently, the agents are typically administered in combination with a sulfa drug.


- 15 That combination drug therapy, however, has clear shortcomings. Many patients exhibit severe allergic reactions to sulfa drugs, and the therapy must be discontinued prior to effective treatment of the disease.

It thus would be desirable to have new therapies to treat parasitic related diseases, such as toxoplasmosis, cryptosporidiosis, leishmaniasis and malaria.

SUMMARY OF THE INVENTION

- 20 I have now found new compounds that exhibit significant anti-parasitic activity and will be useful to treat subjects suffering from or susceptible to various parasitic related disorders and diseases, including but not limited to toxoplasmosis, cryptosporidiosis, leishmaniasis and/or malaria.

- 25 More specifically, in a first aspect, compounds of the following Formula I are provided:



- 3 -

wherein Ar is optionally substituted carbocyclic aryl or optionally substituted heteroaromatic;

- 5 W is a chemical bond, optionally substituted amino (e.g. -NH-), an optionally substituted alkylene group preferably having 1 to about 3 carbons, more preferably 1 or 2 carbon atoms such as -CH₂- or -CH₂CH₂-, or aminoalkylene having 1 nitrogen and 1 or 2 carbon atoms (e.g. -CH₂NH-);

X is nitrogen or carbon;

- 10 Z represents a chemical bond (i.e. a direct bridge to provide a carbazole), optionally substituted methylene or ethylene (i.e. optionally substituted -CH₂- or -CH₂CH₂-), optionally substituted vinyl (i.e. optionally substituted -CH=CH-), optionally substituted azamethinyl, optionally substituted azamethylene, O, S, or optionally substituted N, or Z represents hydrogens or other non-linked substituents
15 on each phenyl group (i.e. Z is not a bridge group to thereby provide a diphenylamine);


- each R¹ and R² independently may be halogen; amino; hydroxy; nitro; azido; optionally substituted alkyl preferably having 1 to about 12 carbon atoms; optionally substituted alkenyl preferably having 2 to about 12 carbon atoms; optionally
20 substituted alkynyl preferably having 2 to about 12 carbon atoms; optionally substituted alkoxy preferably having 1 to about 12 carbon atoms; optionally substituted aminoalkyl preferably having 1 to about 12 carbon atoms; optionally substituted alkanoyl optionally having 1 to about 12 carbon atoms; optionally substituted alkylthio preferably having 1 to about 12 carbon atoms; optionally
25 substituted alkylsulfinyl preferably having 1 to about 12 carbon atoms; optionally substituted alkylsulfonyl preferably having 1 to about 12 carbon atoms; optionally substituted carbocyclic aryl; or optionally substituted heteroaromatic or heteroalicyclic preferably having from 1 to 3 separate or fused rings and with 1 to 3 hetero (N, O or S) atoms;

- 4 -

m and n are each independently an integer of from 0 (where a ring is fully-hydrogen substituted) to 4; and pharmaceutically acceptable salts thereof.


As discussed above, Z in the above Formula I can be non-linked hydrogen or other substituents on each phenyl group, such as compounds of the following Formula

5 IA:




10 wherein in Formula IA, Ar, X, W, R¹ and R² are the same as defined above for Formula I; and m and n are each independently an integer of from 0 (where a ring is fully-hydrogen substituted) to 5; and pharmaceutically acceptable salts thereof.

Preferred compounds of the invention include those of Formula I where W is optionally substituted alkylene, particularly C₁₋₃alkylene, or optionally substituted
 15 nitrogen, even more preferably compounds of the following Formula II or IIA:



20 wherein in Formulae II and IIA, Ar, Z, R¹, R², m and n are each the same as defined above for Formula I; and pharmaceutically acceptable salts thereof.

Preferred compounds of the invention also include those where the aryl group (Ar) is a single or fused group, such as compounds of the following Formula III:



- 5 -



wherein in Formula III, T, U and V are each independently optionally substituted carbon, or optionally substituted nitrogen;

each R^3 is independently selected from the same group of substituents as identified above for R^1 and R^2 ; or two R^3 groups on adjacent ring atoms are taken together to form a fused carbocyclic aryl, heteroaromatic, cycloalkyl or heteroalicyclic ring having from 5 to about 7 ring member,

o is an integer of from 0 (where the ring is fully hydrogen substituted) to 5;

W, X, R^1 , R^2 , m and n are each the same as defined above for Formula I; and pharmaceutically acceptable salts thereof.

Particularly preferred compounds of the invention include those of the following Formulae IV and IVA:



wherein in each of Formulae IV and IVA, U and V are each independently optionally substituted carbon, or optionally substituted nitrogen;

Z, X, W, R^1 , R^2 , m and n are each the same as defined above for Formula I; and pharmaceutically acceptable salts thereof.

As mentioned above, compounds of the invention (i.e. compounds of Formulae I, IA, II, IIA, III, IV and IVA) are useful for a number of therapeutic applications. In particular, the invention includes methods for treatment and/or

- 6 -

prophylaxis of parasitic related diseases, including diseases or disorders associated with *Toxoplasma gondii*, *Pneumocystis carinii*, *Cryptosporidium* including *Cryptosporidium parvum*, *Leishmania*, *Plasmodium vivax*, *P. falciparum*, *P. malarie*, and/or *P. ovale* infections. Compounds of the invention also will be useful for
5 treatment and/or prophylaxis against tuberculosis, particularly in immunocompromised patients, such as AIDS patients, who may have enhanced susceptibility to tuberculosis. The treatment methods of the invention in general comprise administration of a therapeutically effective amount of a compound of the invention to a patient in need thereof.

10 Compounds of the invention are especially useful for treatment of a mammal, particularly a primate such as a human, suffering from or susceptible to toxoplasmosis. Compounds of the invention also are useful for treatment of a mammal, particularly a primate such as a human, suffering from or susceptible to other parasite-related diseases and disorders such as cryptosporidiosis, leishmaniasis
15 and malaria.

Compounds of the invention are particularly useful for treatment of subjects that are susceptible to such parasitic related disorders and diseases, i.e. prophylactic treatment. For instance, compounds of the invention may be administered as prophylactic treatment to AIDS patients and patients receiving immunosuppressive
20 cancer treatments, who are particularly susceptible to toxoplasmosis, cryptosporidiosis, leishmaniasis and other parasitic related disorders and diseases. Unless otherwise indicated, references herein to "treatment," "therapy," or the like are inclusive of treating a subject that is suffering from a targetted disease or disorder, as well as prophylactic treatment, i.e. treating a subject that may be susceptible to such a
25 disorder or disease.

Particularly preferred compounds of the invention exhibit inhibition activity in a standard dihydrofolate reductase assay e.g. as disclosed in Example 72 which follows. References herein to a "standard dihydrofolate reductase assay" refer to an assay of the protocol set forth in that Example 72 which follows, and which includes
30 spectrophotometric assay of dihydrofolate reductase without test compound (control)

- 7 -

and then such assay of dihydrofolate reductase in the presence of varying concentrations of test compound.


Without being bound by theory, it is believed compounds of the invention can exhibit potent and selective anti-parasitic activity upon administration to a subject due to the presence of the two fused or unfused phenyl groups (i.e. the phenyl groups that are optionally substituted by R^1 and R^2 in Formula I above). See, for instance, the results set forth in Example 72 which follows. More particularly, it is believed that one of those phenyl groups can interact hydrophobically with lipophilic amino acid residues in the active site of dihydrofolate reductase in both the parasite and host, only the active site of the parasite enzyme is sufficiently spacious to accommodate both phenyl groups of compounds of the invention, thereby providing for selective treatment against the parasite.

The invention also provides pharmaceutical compositions that comprise one or more compounds of the invention and a suitable carrier for the compositions.




Other aspects of the invention are disclosed *infra*.

DETAILED DESCRIPTION OF THE INVENTION

As discussed above, we have now discovered that compounds of the following Formula I, IA, II, IIA, III, IV and IVA (i.e. compounds of the invention) are useful for therapeutic applications, particularly against parasitic-related diseases and disorders.



- 8 -



wherein Ar, W, X, Z, R¹, R², R³, T, U, V, m, n and o are as defined above.

Preferred compounds of the invention are amino pyrimidine compounds, particularly 2,4-diaminopyrimidine and condensed 2,4-diaminopyrimidine compounds.

20 Suitable halogen substituent groups of compounds of Formulae I, IA, II, IIA, III, IV and IVA, as defined above (i.e. compounds of the invention) include F, Cl, Br and I. Alkyl groups of compounds of the invention typically have from 1 to about 12 carbon atoms, more preferably 1 to about 8 carbon atoms, still more preferably 1 to about 6 carbon atoms, even more preferably 1, 2, 3 or 4 carbon atoms, or still more
25 preferably 1, 2 or 3 carbon atoms. As used herein, the term alkyl unless otherwise modified refers to both cyclic and noncyclic groups, although of course cyclic groups

- 9 -

will comprise at least three carbon ring members. Preferred alkenyl and alkynyl groups of compounds of the invention have one or more unsaturated linkages and typically from 2 to about 12 carbon atoms, more preferably 2 to about 8 carbon atoms, still more preferably 2 to about 6 carbon atoms, even more preferably 1, 2, 3 or 4 carbon atoms. The terms alkenyl and alkynyl as used herein refer to both cyclic and noncyclic groups, although straight or branched noncyclic groups are generally more preferred. Preferred alkoxy groups of compounds of the invention include groups having one or more oxygen linkages and from 1 to about 12 carbon atoms, more preferably from 1 to about 8 carbon atoms, and still more preferably 1 to about 6 carbon atoms, even more preferably 1, 2, 3 or 4 carbon atoms. Preferred alkylthio groups of compounds of the invention include those groups having one or more thioether linkages and from 1 to about 12 carbon atoms, more preferably from 1 to about 8 carbon atoms, and still more preferably 1 to about 6 carbon atoms. Alkylthio groups having 1, 2, 3 or 4 carbon atoms are particularly preferred. Preferred alkylsulfinyl groups of compounds of the invention include those groups having one or more sulfoxide (SO) groups and from 1 to about 12 carbon atoms, more preferably from 1 to about 8 carbon atoms, and still more preferably 1 to about 6 carbon atoms. Alkylsulfinyl groups having 1, 2, 3 or 4 carbon atoms are particularly preferred. Preferred alkylsulfonyl groups of compounds of the invention include those groups having one or more sulfonyl (SO₂) groups and from 1 to about 12 carbon atoms, more preferably from 1 to about 8 carbon atoms, and still more preferably 1 to about 6 carbon atoms. Alkylsulfonyl groups having 1, 2, 3 or 4 carbon atoms are particularly preferred. Preferred aminoalkyl groups include those groups having one or more primary, secondary and/or tertiary amine groups, and from 1 to about 12 carbon atoms, more preferably 1 to about 8 carbon atoms, still more preferably 1 to about 6 carbon atoms, even more preferably 1, 2, 3 or 4 carbon atoms. Secondary and tertiary amine groups are generally more preferred than primary amine moieties. Suitable heteroaromatic groups of compounds of the invention contain one or more N, O or S atoms and 1-3 separate or fused rings and include, e.g., coumarinyl including 8-coumarinyl, quinolinyl including 8-quinolinyl, pyridyl, pyrazinyl, pyrimidyl, furyl, pyrrolyl, thienyl, thiazolyl, oxazolyl, oxidizolyl, triazole, imidazolyl, indolyl, benzofuranyl and benzothiazol. Optionally substituted pteridine is a particularly

- 10 -

preferred Ar group of compounds of Formula I, IA, II, and III (i.e. in Formula III U and V are each nitrogen, and two R³ groups are taken together to form a pteridine group), particularly pteridine substituted at the 6 position to the W group linkage. Suitable heteroalicyclic groups of compounds of the invention contain one or more N,
5 O or S atoms and 1-3 separate or fused rings and include, e.g., tetrahydrofuranyl, thienyl, tetrahydropyranyl, piperidiny, morpholino and pyrrolindiny groups. Suitable carbocyclic aryl groups of compounds of the invention include single and multiple ring compounds, including multiple ring compounds that contain separate and/or fused aryl groups. Typical carbocyclic aryl groups of compounds of the
10 invention contain 1 to 3 separate or fused rings and from 6 to about 18 carbon ring atoms. Specifically preferred carbocyclic aryl groups include phenyl; naphthyl including 1-naphthyl and 2-naphthyl; biphenyl; phenanthryl; anthracyl; and acenaphthyl.

Suitable aralkyl groups of compounds of the invention include single and
15 multiple ring compounds, including multiple ring compounds that contain separate and/or fused aryl groups. Typical aralkyl groups contain 1 to 3 separate or fused rings and from 6 to about 18 carbon ring atoms. Preferred aralkyl groups include benzyl and methylenenaphthyl (-CH₂-naphthyl), and other carbocyclic aralkyl groups, as discussed above.

20 As discussed above, W groups of Formulae I, IA, III, IV and IVA suitably are optionally substituted C₁₋₃ alkylene, more preferably CH₂ or CH₂CH₂, or an optionally substituted amino such as -NH-, -NH(CH₃)-, etc., or optionally substituted aminoalkylene such as -CH₂NH-, -NHCH₂-, -CH₂CH₂NH-, -NHCH₂CH₂-, or -CH₂NHCH₂-. carbon atoms, still more preferably 1, 2 or 3 carbon atoms.

25 Particularly preferred Z groups of Formula I, II, IIA, III, IV and IVA include -CH₂-, -CH₂CH₂-, -CH=CH-, NH, O and S, with -CH=CH- being particularly preferred.

Specifically preferred compounds of the invention include the following:

N-(2,4-diaminopteridin-6-yl)methyl-N,N-diphenylamine;

30 2,4-diamino-6-(carbazol-5-yl)methylpteridine;

- 11 -

- 2,4-diamino-6-(9,10-dihydroacridin-9-yl)methylpteridine;
- N-[(2,4-diaminopteridin-6-yl)methyl]phenoxazine;
- N-[(2,4-diaminopteridin-6-yl)methyl]phenothiazine;
- N-[(2,4-diaminopteridin-6-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine;
- 5 N-[(2,4-diaminopteridin-6-yl)methyl]dibenz[*b,f*]azepine;
- N-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]-N,N-diphenylamine;
- N-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]-N,N-diphenylamine;
- N-[(2,4-diaminoquinazolin-6-yl)methyl]-N,N-diphenylamine;
- N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine;
- 10 N-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine;
- N-[(2,4-diaminopyrimidin-6-yl)methyl]-N,N-diphenylamine;
- N-[(2,4-diaminopteridin-6-yl)methyl]carbazole;
- N-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]carbazole;
- N-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]carbazole;
- 15 N-[(2,4-diaminoquinazolin-6-yl)methyl]carbazole;
- N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]carbazole;
- N-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]carbazole;
- N-[(2,4-diaminopyrimidin-6-yl)methyl]carbazole;
- N-[(2,4-diaminopteridin-6-yl)methyl]-9,10-dihydroacridine;
- 20 N-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]-9,10-dihydroacridine;
- N-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]-9,10-dihydroacridine;
- N-[(2,4-diaminoquinazolin-6-yl)methyl]-9,10-dihydroacridine;
- N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-9,10-dihydroacridine;

- 12 -

- N-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]-9,10-dihydroacridine;
N-[(2,4-diaminopyrimidin-6-yl)methyl]-9,10-dihydroacridine;
N-[(2,4-diaminopteridin-6-yl)methyl]phenoxazine;
9-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]phenoxazine;
5 9-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]phenoxazine;
9-[(2,4-diaminoquinazolin-6-yl)methyl]phenoxazine;
9-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]phenoxazine;
9-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]phenoxazine;
9-[(2,4-diaminopyrimidin-6-yl)methyl]phenoxazine;
10 N-[(2,4-diaminopteridin-6-yl)methyl]phenothiazine;
9-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]phenothiazine;
9-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]phenothiazine;
9-[(2,4-diaminoquinazolin-6-yl)methyl]phenothiazine;
9-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]phenothiazine;
15 9-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]phenothiazine;
9-[(2,4-diaminopyrimidin-5-yl)methyl]phenothiazine;
N-[(2,4-diaminopteridin-6-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine;
N-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine;
N-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine;
20 9-[(2,4-diaminoquinazolin-6-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine;
9-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine;
9-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine;
9-[(2,4-diaminopyrimidin-5-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine;

- 13 -

- N-[(2,4-diaminopteridin-6-yl)methyl]dibenz[*b,f*]azepine;
- 9-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]dibenz[*b,f*]azepine;
- 9-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]dibenz[*b,f*]azepine;
- 9-[(2,4-diaminoquinazolin-6-yl)methyl]dibenz[*b,f*]azepine;
- 5 9-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]dibenz[*b,f*]azepine;
- 9-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]dibenz[*b,f*]azepine;
- 9-[(2,4-diaminopyrimidin-6-yl)methyl]dibenz[*b,f*]azepine;
- N-(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)benzhydramine;
- N-(2,4-diaminoquinazolin-6-yl)benzhydramine;
- 10 N-[(2,4-diaminopyrimidin-5-yl)methyl]benzhydramine;
- N-[(2,4-diaminopyrimidin-5-yl)ethyl]benzhydramine;
- 9-[N-(2,4-diaminoquinazolin-6-yl)amino]fluorene;
- 9-[N-(2,4-diaminoquinazolin-5-yl)methylamino]fluorene;
- 9-[N-[2-(2,4-diaminoquinazolin-5-yl)ethyl]amino]fluorene;
- 15 5-[N-(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]-5*H*-10,11-dihydro-dibenzo[*a,d*]cycloheptene;
- 5-[N-(2,4-diaminoquinazolin-6-yl)amino]-5*H*-10,11-dihydrodibenzo[*a,d*]cycloheptene;
- 5-[N-(2,4-diaminopyrimidin-5-yl)methylamino]-5*H*-10,11-dihydrodibenzo
- 20 [a,d]cycloheptene;
- 5-[N-[2-(2,4-diaminopyrimidin-5-yl)ethyl]amino]-5*H*-10,11-dihydrodibenzo [a,d]cycloheptene;
- 5-[N-(2,4-diaminopyrimidin-[2,3-*d*]pyrimidin-6-yl)amino]-5*H*-dibenzo [a,d]cycloheptene;
- 25 5-[N-(2,4-diaminoquinazolin-6-yl)amino]-5*H*-dibenzo [a,d]cycloheptene;

- 14 -

5-[N-(2,4-diaminopyrimidin-5-yl)methylamino]-5*H*-dibenzo[*a,d*]cycloheptene; and
5-[N-[2-(2,4-diaminopyrimidin-5-yl)ethyl]amino]-5*H*-dibenzo[*a,d*]cycloheptene; and
pharmaceutically acceptable salts thereof.

Compounds of the invention may be readily prepared. For instance, a suitable
5 aryl compound (Ar group precursor) linked to W group precursor that has a reactive
carbon (e.g. a carbon substituted with a suitable leaving group such as halogen e.g. Br
or I) can be reacted in the presence of a hydride or other suitable base with a fused
ring compound, or a diphenyl amine to provide compounds of the invention. Thus,
for example, to synthesize compounds of Formula I where Z is a chemical bond and
10 W is alkylene, an optionally substituted carbazole may be reacted in the presence a
molar excess of sodium hydride with a haloalkylaryl compound. To synthesize
compounds where W is optionally substituted amino or aminoalkylene, the
corresponding aryl compound can be employed, e.g. an aminoaryl or alkylaminoaryl
compound, can be employed. To prepare compounds where X is a hetero atom, a
15 phenoxazine, phenothiazine or phenazine can be reacted under similar conditions. A
diphenylamine can be reacted to provide compounds of Formula IA. See the
examples which follow for exemplary reaction conditions.

As discussed above, preferred compounds of the invention exhibit good
inhibition activity in a standard dihydrofolate reductase assay. In particular, preferred
20 compounds of the invention exhibit in a standard dihydrofolate reductase assay an
IC₅₀ (:M) of less than about 50 against rat liver dihydrofolate reductase, and other
mammalian including human dihydrofolate reductase; more preferably an IC₅₀ (:M) of
less than about 25 against rat liver dihydrofolate reductase, and other mammalian
including human dihydrofolate reductase; even more preferably an IC₅₀ (:M) of less
25 than about 10 against rat liver dihydrofolate reductase, and other mammalian
including human dihydrofolate reductase.

Preferred compounds of the invention also include those that exhibit in a
standard dihydrofolate reductase assay an IC₅₀ (:M) of less than about 20 against *P.*
carinii dihydrofolate reductase, more preferably an IC₅₀ (:M) of less than about 10
30 against *P. carinii* dihydrofolate reductase, still more preferably an IC₅₀ (:M) of less

- 15 -

than about 5 against *P. carinii* dihydrofolate reductase, even more preferably an IC_{50} (:M) of less than about 1 or 2 against *P. carinii* dihydrofolate reductase. Preferred compounds of the invention also exhibit in a standard dihydrofolate reductase assay an IC_{50} (:M) of less than about 10 against *T. gondii* dihydrofolate reductase, more
5 preferably an IC_{50} (:M) of less than about 5 against *T. gondii* dihydrofolate reductase, still more preferably an IC_{50} (:M) of less than about 1 against *T. gondii* dihydrofolate reductase, even more preferably an IC_{50} (:M) of less than about 0.1 against *T. gondii* dihydrofolate reductase.

Particularly preferred compounds of the invention include those compounds
10 that exhibit selective activity for a targeted disorder or microorganism relative to activity against host proliferative tissue (e.g. bone marrow, oral/intestinal mucosa and the like).

Compounds of the invention may be used in therapy in conjunction with other medicaments. For example, compounds of the invention may be administered in
15 combination with agents used for treatment against parasitic infections and associated diseases and disorders. For instance, compounds of the invention can be administered in conjunction with a sulfa drug such as sulfacetamide, sulfadiazine, sulfadimethoxine, sulfadimidine, sulfamethoxazole, sulfathiazole, sulfaguanidine and the like. However, preferred compounds of the invention will be sufficiently potent to
20 enable effective therapy without use of another active pharmaceutical agent.

Compounds of the invention can be suitably administered to a subject by a variety of routes including oral, parenteral (including intraperitoneal, subcutaneous, intravenous, intradermal or intramuscular injection), topical (including transdermal, buccal or sublingal), or nasal. Administration also suitably may be via inhalation or
25 rectally. The optimal dose can be determined by conventional means.

Compounds of the present invention are suitably administered to a subject in the protonated and water-soluble form, e.g., as a pharmaceutically acceptable salt of an organic or inorganic acid, e.g., hydrochloride, sulfate, hemi-sulfate, phosphate, nitrate, acetate, oxalate, citrate, maleate, mesylate, etc., or if an acid group is present

- 16 -

on the therapeutic compound, a base addition salt can be employed, e.g. a Na or K salt.

Compounds of the invention can be employed, either alone or in combination with one or more other therapeutic agents as discussed above, as a pharmaceutical composition in mixture with conventional excipient, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral, oral, enteral, topical or intranasal application which do not deleteriously react with the active compounds and are not deleterious to the recipient thereof. Suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions, alcohol, vegetable oils, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, petroethral fatty acid esters, hydroxymethyl-cellulose, polyvinylpyrrolidone, etc. The pharmaceutical preparations can be sterilized and if desired mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously react with the active compounds.

For parenteral application, particularly suitable are solutions, preferably oily or aqueous solutions as well as suspensions, emulsions, or implants, including suppositories. Ampules are convenient unit dosages.

For enteral application, particularly suitable are tablets, dragees or capsules having talc and/or carbohydrate carrier binder or the like, the carrier preferably being lactose and/or corn starch and/or potato starch. A syrup, elixir or the like can be used wherein a sweetened vehicle is employed. Sustained release compositions can be formulated including those wherein the active component is protected with differentially degradable coatings, e.g., by microencapsulation, multiple coatings, etc.

As discussed above, the compounds of this invention are particularly useful in the treatment of mammalian subjects, e.g. primates particularly humans, to provide treatment from infection a variety of microorganisms including *Toxoplasma gondii*, *Pneumocystis carinii*, *Cryptosporidium* including *Cryptosporidium parvum*, *Leishmania*, *Plasmodium vivax*, *P. falciparum*, *P. malarie*, and *P. ovale*. Such subjects include those afflicted with toxoplasmosis, cryptosporidiosis, leishmaniasis

- 17 -

or malaria. Such subjects often will be immunocompromised, e.g. the subjects may suffer a primary infection from a retrovirus such as human immunodeficiency virus. The patients also may be immunocompromised as a result of other circumstances, e.g. due to cancer therapy.

5 Compounds of the invention also will be useful for veterinary applications, e.g. to treat mammals such as livestock e.g. cattle, sheep, goats, cows, swine and the like and dogs and cats and other pets and domesticated animals; poultry such as chickens, ducks, geese, turkeys and the like. In particular, the compounds will be useful to treat animals that may carry *T. gondii* such as sheep, pigs and cats.

10 It will be appreciated that the actual preferred amounts of active compounds used in a given therapy will vary according to the specific compound being utilized, the particular compositions formulated, the mode of application, the particular site of administration, etc. Optimal administration rates for a given protocol of
15 administration can be readily ascertained by those skilled in the art using conventional dosage determination tests conducted with regard to the foregoing guidelines. In general, a suitable effective dose of one or more compounds of Formulae I, IA, II, IIA, III, IV, IVA, will be in the range of from 0.01 to 100 milligrams per kilogram of bodyweight of recipient per day, preferably in the range of from 0.01 to 20 milligrams per kilogram bodyweight of recipient per day, more preferably in the range of 0.05 to
20 4 milligrams per kilogram bodyweight of recipient per day. The desired dose is suitably administered once daily, or several sub-doses, e.g. 2 to 4 sub-doses, are administered at appropriate intervals through the day, or other appropriate schedule.

All documents mentioned herein are incorporated herein by reference in their entirety. The following non-limiting examples are illustrative of the invention.

25 Example 1: N-(2,4-Diaminopteridin-6-yl)methyl-N,N-diphenylamine (Formula I: Ar = 2,4-diaminopteridin-6-yl); X = N; W = CH₂; Z = non-linked hydrogens on each phenyl group; m = n = 0).

 Powdered NaH (50 mg, 2.1 mmol) is added to a stirred solution of diphenylamine (1.3 g, 0.77 mmol) in dry THF (10 mL) at 0 °C under N₂. After 10
30 min, 2,4-diamino-6-bromomethylpteridine hydrobromide (100 mg, 0.3 mmol) is

- 18 -

added and the reaction mixture is allowed to come to room temperature and left to stir for 2 days. The excess NaH is decomposed with MeOH (1 mL) and the mixture is concentrated to dryness by rotary evaporation. Flash chromatography on silica gel with 95:5 CHCl₃-MeOH as the eluent affords the product, N-(2,4-diaminopteridin-6-yl)methyl-N,N-diphenylamine, as a bright-yellow powder (56 mg, 54% yield); mp >250 °C dec.; MS (FAB) *m/z* (*M* + 1) = 344; IR (KBr) ν 3450, 3340, 3170, 1630, 1590, 1550, 1490, 1450, 1360, 1220 cm⁻¹; ¹H NMR (*d*₆-DMSO) δ 5.10 (s, 2H, CH₂), 6.70 (m, 10H, aromatic), 8.60 (s, 1H, C₇-H. Anal. Calcd for C₁₉H₁₇N₇·0.8H₂O: C, 63.73; H, 5.23; N, 27.40. Found: C, 64.15; H, 4.85; N, 27.07.

10 Example 2: Preparation of 2,4-Diamino-6-(carbazol-5-yl)methylpteridine (Formula I: Ar=6-(2,4-diaminopteridine); X=N; W=CH₂; Z=chemical bond; m=n=0).

NaH (60% oil suspension containing 44 mg, 1.88 mmol) was added to a stirred solution of carbazole (65.5 mg, 0.392 mmol) in dry THF (10 mL) at 0°C under N₂. After 10 minutes, 2,4-diamino-6-bromo-methylpteridine hydrobromide (100 mg, 0.392 mmol) was added and the reaction mixture was allowed to come to room temperature and left to stir for 2 days. The excess NaH was decomposed with several drops of MeOH followed by three drops of glacial AcOH, and the mixture was concentrated to dryness by rotary evaporation. Flash chromatography on silica gel with 85:15 CHCl₃-MeOH followed by 1:1 CHCl₃-MeOH as the eluent. Appropriate fractions were pooled and evaporated to a yellow solid which was dried in vacuo at 70°C overnight, to provide the title compound, 2,3-diamino-6-(carbazol-5-yl)methylpteridine, yield 10 mg (<10%). MS (FAB) *m/z* (*M* + 1) = 342.2265. Anal. Calcd. for C₁₉H₁₅N₇ 1/6CHCl₃: C, 63.72; H, 4.23. Found: C, 63.41; H, 4.11.

25 Example 3: Preparation of 2,4-Diamino-6-(9,10-dihydroacridin-9-yl)methylpteridine (Formula I: Ar=6-(2,4-diaminopteridine); X=N; W=CH₂; Z=CH₂; m=n=0).

Raney Ni (1 g) was added to a solution of acridine (1 g, 5.58 mmol) in EtOH (20 mL), and the mixture was shaken under a hydrogen atmosphere (50 psi) for 2 days. Additional EtOH (200 mL) was added, and the Ni catalyst was removed by

- 19 -

filtration. Evaporation of filtrate and recrystallization of the residue from MeOH afforded colorless needles of 5,10-dihydroacridine (0.7 g, 70% yield); mp 169-170°C. A portion of this material (0.224 g, 1.18 mmol) was dissolved in dry THF (10 mL) under N₂, and the solution was cooled to 0 °C, and NaH (50% oil suspension
5 containing 0.119 g, 4.7 mmol) was added in small portions with magnetic stirring. After 10 min, 2,4-diamino-6-bromomethylpteridine hydrobromide (0.100 g, 0.392 mmol) was added slowly with continued stirring, and the reaction mixture was allowed to warm to room temperature and stirred overnight. Excess sodium hydride was destroyed with a small drops of AcOH, and the solvents were removed by rotary
10 evaporation. Flash chromatography of the residue on silica gel with 9:1 CHCl₃-MeOH as the eluent afforded the title compound, 2,4-diamino-6-(9,10-dihydroacridin-9-yl)methylpteridine, as a yellow-brown solid (ca. 10% yield); mp >250 °C dec. MS (FAB *m/z* (M + 1) = 370.1785.

Example 4: Preparation of N-[(2,4-Diaminopteridin-6-yl)methyl]phenoxazine
15 (Formula I: Ar=6-(2,4-diaminopteridine); X=N; W=CH₂; Z=O; m=n=0).

NaH (60% oil suspension containing 51 mg, 2.0 mmol) was added to a stirred solution of phenoxazine (147 mg, 0.784 mmol) in dry THF (10 mL) at 0 °C under N₂. After 10 min, 2,4-diamino-6-bromomethylpteridine hydrobromide (100 mg, 0.392 mmol) was added and the reaction mixture was allowed to come to room temperature
20 and left to stir for 2 days. The excess NaH was decomposed with MeOH (1 mL), and the mixture was concentrated to dryness by rotary evaporation. Flash chromatography on silica gel yielded the title compound, N-[(2,4-diaminopteridin-6-yl)methyl]phenoxazine, as a brown solid; yield 47 mg (34%); mp >250 °C dec. Anal. Calcd. for C₁₉H₁₅N₇O 0.4H₂O: C, 62.60; H, 4.37. Found: C, 62.84; H, 4.10.

25 Example 5: Preparation of N-[(2,4-Diaminopteridin-6-yl)methyl]phenothiazine (Formula I: Ar=6-(2,4-diaminopteridine); X=N; W=CH₂; Z=S; m=n=0).

NaH (60% oil suspension containing 51 mg, 2.0 mmol) was added to a stirred solution of phenoxazine (159 mg, 0.784 mmol) in dry THF (20 mL) at 0°C under N₂.
30 After 10 min, 2,4-diamino-6-bromomethylpteridine hydrobromide (100 mg, 0.392

- 20 -

mmol) was added and the reaction mixture was allowed to come to room temperature and left in stir for 2 days. The excess NaH was decomposed with MeOH (1 mL), and the mixture was concentrated to dryness by rotary evaporation. Flash chromatography on silica gel yielded the title compound, N-[(2,4-diaminopteridin-6-yl)methyl]phenothiazine, as a greenish-yellow solid; yield 20 mg (14%); mp 250 °C dec. Anal. Calcd. for $C_{19}H_{19}N_7 \cdot 5/5CHCl_3$; C, 64.73, H, 4.93, Found: C, 64.55; H 4.90.

Example 6: Preparation of N-[(2,4-Diaminopteridin-6-yl)methyl]-9,10-dihydrodibenz[*b,f*] azepine (Formula I: Ar=6-(2,4-diaminopteridine); X=N; W=CH₂; Z=CH₂CH₂; m=n=0).

NaH (60% oil suspension containing 11 mg, 0.47 mmol) was added to a stirred solution of 9,10-dihydrodibenz[*b,f*]azepine (77 mg, 0.392 mmol) in dry THF (10 mL) at 0 °C under N₂. After 10 minutes, 2,4-diamino-6-bromomethylpteridine hydrobromide (100 mg, 0.392 mmol) was added and the reaction mixture was allowed to come to room temperature and left to stir for 2 days. After the excess NaH was decomposed with a small volume of MeOH, the mixture was poured into H₂O (20 mL) and the product extracted into 85:15 CHCl₃-MeOH (3 x 50 mL). The organic layer was dried over Na₂SO₄ and evaporated, and the residue was purified by preparative TLC (silica gel, 85L15 CHCl₃-MeOH) to obtain the title compound, N-[(2,4-diaminopteridin-6-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine, as a yellow solid (35 mg, 24% yield). Anal. Calcd. for $C_{21}H_{19}N_7 \cdot 1/5 CHCl_3$; C, 64.73; H, 4.93. Found: C, 64.55; H, 4.90.

Example 7: Preparation of N-[(2,4-Diaminopteridin-6-yl)methyl]dibenz[*b,f*]azepine (Formula I: Ar=6-(2,4-diaminopteridine); X=N; W=CH=CH; Z=CH₂; m=n=0).

NaH (60% oil suspension containing 44 mg, 1.88 mmol) was added to a stirred solution of dibenz[*b,f*]azepine (76 mg, 0.392 mmol) in dry THF (10 mL) at 0 °C under N₂. After 10 min, 2,4-diamino-6-bromomethylpteridine hydrobromide (100 mg, 0.392 mmol) was added and the reaction mixture was allowed to come to room temperature and left to stir for overnight. After the excess NaH was decomposed with

- 21 -

MeOH (0.5 mL) and 3 drops of glacial AcOH, the mixture was poured into H₂O (20 mL) and the product was extracted into 85:15 CHCl₃:MeOH (3 x 50mL). The organic layers was dried over Na₂SO₄ and evaporated and the residue was purified by column chromatography (flash silica gel. 85:15 CHCl₃:MeOH) to obtain the title compound,
5 N-[(2,4-diaminopteridin-6-yl)methyl]dibenz[*b,f*]azepine, as a yellow solid (25 mg, 17% yield). MS (FAB) *m/z* = *M* + 1) 367.199. Anal. Calcd. for C₂₁H₁₇N₇ ¼CHCl₃: C, 64.25; H, 4.38; N, 24.68: Found: C, 64.06; H, 4.19, N, 23.82.

Example 8: N-[(2,4-Diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]-N,N-diphenylamine (Formula I: Ar = 2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl; X = N; W =
10 CH₂; Z = non-linked hydrogens on each phenyl group; Z = CH₂; m = n = 0) is prepared similarly as disclosed in Example 1 above by using N,N-diphenylamine (1.3 g, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[2,3-*d*]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 9: N-[(2,4-Diaminopyrido[3,2-*d*]pyrimidine-6-yl)methyl]-N,N-diphenylamine (Formula I: Ar = 2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl; X = N; W =
15 CH₂; Z = non-linked hydrogens on each phenyl group; Z = CH₂; m = n = 0) is prepared similarly as disclosed in Example 1 above by using diphenylamine (1.3 g, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[2,3-*d*]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by
20 chromatography.

Example 10: N-[(2,4-Diaminoquinazolin-6-yl)methyl]-N,N-diphenylamine (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; X = N; W = CH₂; Z = non-linked
hydrogens on each phenyl group; m = n = 0) is prepared similarly as disclosed in
25 Example 1 above by using diphenylamine (1.3 g, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylquinazoline hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 11: N-[(2,4-Diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine (Formula I: Ar = 2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl; W = CH₂;
30 X = N; Z = non-linked hydrogens on each phenyl group; m = n = 0).

- 22 -

Step 1. A mixture of 2,4-diamino-5-methylthieno[2,3-*d*]pyrimidine (1.3 g, 7.2 mmol) and pivalic anhydride (33 g, 18 mmol) in dry pyridine is refluxed under N₂ overnight, then cooled and evaporated under reduced pressure. The residue is taken up in Et₂O (500 mL), the solution is washed with 5% NaHCO₃ (2 x 100 mL),
5 the organic layer is dried and evaporated, and the residue is recrystallized from Et₂O to obtain the 2,4-bis(pivaloylamino) derivative.

Step 2. The 2,4-bis(pivaloylamino) compound (2.6 g, 7.5 mmol) obtained in Step 1 is dissolved in CHCl₃ (600 mL), and the solution is cooled to 0 °C and treated with N-bromosuccinimide (1.6 g, 9.0 mmol) and benzoyl peroxide (0.2 g, 0.8 mmol). The solution is stirred overnight at room temperature, treated with
10 additional N-bromosuccinimide (9.1 g, 51 mmol) and benzoyl peroxide (1.2 g, 4.8 mmol), and left to stir for a total of 6 days. The yellow solid which precipitates during this time is filtered off, and the filtrate is washed with H₂O (2 x 50 mL), dried and evaporated to obtain 2,4-bis(pivaloylamino)-5-bromomethyl-6-bromothieno[2,3-*d*]pyrimidine.
15

Step 3. A mixture of 2,4-bis(pivaloylamino)-5-bromomethyl-6-bromothieno[2,3-*d*]pyrimidine prepared in Step 2 above (200 mg, 0.4 mmol), diphenylamine (1.3 g, 0.77 mmol) and NaH (50 mg, 2.1 mmol) in dry THF (10 mL) is stirred at room temperature for 2 days, the excess NaH is decomposed with MeOH (1
20 mL), the solvent is evaporated, and the residue is chromatographed on silica gel to obtain 2,4-bis(pivaloylamino)-5-(N,N-diphenylaminomethyl)-6-bromothieno[2,3-*d*]pyrimidine.

Step 4. To remove the pivaloyl groups, 2,4-bis(pivaloylamino)-5-(N,N-diphenylaminomethyl)-6-bromothieno[2,3-*d*]pyrimidine prepared in Step 3 above
25 (224 mg, 0.4 mmol) is stirred in a mixture of MeOH (100 mL) and 1 N NaOH (50 mL) at 35 °C overnight. The precipitated solid is collected, washed with H₂O, and air-dried.

Step 5. To remove the remaining bromine atom, a solution of the compound prepared in Step 4 above (118 mg, 0.3 mmol) in 1:1 THF-H₂O (30 mL) is

- 23 -

cooled to 0 °C and treated with PdCl₂ (240 mg, 0.6 mmol) and NaBH₄ (110 mg, 3.0 mmol). The mixture is left to stir at room temperature for 8 hrs, the THF is evaporated under reduced pressure and replaced with an equal volume of H₂O, and the product is extracted several times with CHCl₃. The combined organic layers are dried over Na₂SO₄ and evaporated, and the residue is purified by silica gel chromatography using a mixture of CHCl₃ and MeOH as the eluent to afford the desired compound, N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-6-yl)methyl]-N,N-diphenylamine. The final product and its intermediates can be purified by chromatography.

Example 12: N-[(2,4-Diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine (Formula I: Ar = 2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl; W = CH₂; X = N; Z = non-linked hydrogens on each phenyl group; m = n = 0) is prepared similarly to N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-6-yl)methyl]-N,N-diphenylamine as disclosed in Example 11 above by using diphenylamine (1.3 g, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-chloromethylfuro[2,3-*d*]pyrimidine (60 mg, 0.3 mmol). The product can be purified by chromatography.

Example 13: N-[(2,4-Diaminopyrimidin-6-yl)methyl]-N,N-diphenylamine (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH₂; X = N; Z = non-linked hydrogens on each phenyl group; m = n = 0) is prepared similarly to N-(2,4-diaminopteridin-6-yl)methyl-N,N-diphenylamine as disclosed above by using diphenylamine (1.3 g, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-bromomethylpyrimidine hydrobromide (86 mg, 0.3 mmole). The product can be purified by chromatography.

Example 14: N-[(2,4-Diaminopteridin-6-yl)methyl]carbazole (Formula I: Ar = 2,4-diaminopteridin-6-yl; W = CH₂; X = N; Z = chemical bond; m = n = 0) is prepared similarly to N-(2,4-diaminopteridin-6-yl)methyl-N,N-diphenylamine as disclosed above by using carbazole (129 mg, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpteridine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

- 24 -

Example 15: N-[(2,4-Diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]carbazole (Formula I: Ar = 2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl; W = CH₂; X = N; Z = chemical bond; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using carbazole (129 mg, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[2,3-*d*]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 16: N-[(2,4-Diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]carbazole (Formula I: Ar = 2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl; W = CH₂; X = N; Z = chemical bond; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using carbazole (129 mg, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[3,2-*d*]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 17: N-[(2,4-Diaminoquinazolin-6-yl)methyl]carbazole (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; W = CH₂; N = X; Z = chemical bond; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using carbazole (129 mg, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylquinaline hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 18: N-[(2,4-Diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]carbazole (Formula I: Ar = 2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl; W = CH₂; X = N; Z = chemical bond; m = n = 0) is prepared similarly to N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed in Example 11 above by using 2,4-diamino-5-methylthieno[2,3-*d*]pyrimidine (1.3 g, 7.2 mmol) in Step 1 and carbazole (129 mg, 0.8 mmol) in Step 3. The final product and its intermediates can be purified by chromatography.

Example 19: N-[(2,4-Diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]carbazole (Formula I: Ar = 2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl; W = CH₂; X = N; Z = chemical bond; m = n = 0) is prepared similarly to N-[(2,4-diaminofuro[2,3-

- 25 -

d]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed in Example 11 above by using carbazole (129 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-chloromethylfuro[2,3-*d*]pyrimidine (60 mg, 0.3 mmol). The product can be purified by chromatography.

5 Example 20: N-[(2,4-Diaminopyrimidin-6-yl)methyl]carbazole (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH₂; X = N; Z = chemical bond; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using carbazole (129 mg, 0.77 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-bromomethylpyrimidine hydrobromide (86 mg, 0.3 mmol). The
10 product can be purified by chromatography.

 Example 21: N-[(2,4-Diaminopteridin-6-yl)methyl]-9,10-dihydroacridine (Formula I: Ar = 2,4-diaminopteridin-6-yl; W = CH₂; N = X; Z = CH₂; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10-dihydroacridine (134 mg, 0.8 mmol), NaH (50 mg, 2.1
15 mmol), and 2,4-diamino-6-bromomethylpteridine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

 Example 22: N-[(2,4-Diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]-9,10-dihydroacridine (Formula I: Ar = 2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl; W = CH₂; X = N; Z = CH₂; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-
20 yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10-dihydroacridine (134 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[2,3-*d*]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

 Example 23: N-[(2,4-Diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]-9,10-dihydroacridine (Formula I: Ar = 2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl; W = CH₂; X = N; Z = CH₂; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-
25 yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10-dihydroacridine (134 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[3,2-*d*]pyrimidine hydrobromide (100 mg, 0.3 mmol). The
30 product can be purified by chromatography.

- 26 -

Example 24: N-[(2,4-Diaminoquinazolin-6-yl)methyl]-9,10-dihydroacridine (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; W = CH₂; X = N; Z = CH₂; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10-dihydroacridine (134 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylquinazoline hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 25: N-[(2,4-Diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-9,10-dihydroacridine (Formula I: Ar = 2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl; W = CH₂; X = N; Z = CH₂; m = n = 0) is prepared similarly to N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed in Example 11 above by using 2,4-diamino-5-methylthieno[2,3-*d*]pyrimidine (1.3 g, 7.4 mmol) in Step 1 and 9,10-dihydroacridine (134 mg, 0.8 mmol) in Step 3. The final product and its intermediates can be purified by chromatography.

Example 26: N-[(2,4-Diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]-9,10-dihydroacridine (Formula I: Ar = 2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl; W = CH₂; X = N; Z = CH₂; m = n = 0) is prepared similarly to N-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed in Example 11 above by using 9,10-dihydroacridine (134 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-chloromethylfuro[2,3-*d*]pyrimidine (60 mg, 0.3 mmol). The product can be purified by chromatography.

Example 27: N-[(2,4-Diaminopyrimidin-6-yl)methyl]-9,10-dihydroacridine (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH₂; X = N; Z = CH₂; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10-dihydroacridine (134 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-bromomethylpyrimidine hydrobromide (86 mg, 0.3 mmol). The product can be purified by chromatography.

Example 28: N-[(2,4-Diaminopteridin-6-yl)methyl]phenoxazine (Formula I: Ar = 2,4-diaminopteridin-6-yl; W = CH₂; X = N; Z = O; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using phenoxazine (146 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-

- 27 -

diamino-6-bromomethylpteridine hydrobromide (100 mg, 0.3 mmol). The final product can be purified by chromatography.

Example 29: 9-[(2,4-Diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]phenoxazine (Formula I: Ar = 2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl; W = CH₂; X = N; Z = O; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using phenoxazine (146 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[2,3-*d*]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 30: 9-[(2,4-Diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]phenoxazine (Formula I: Ar = 2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl; W = CH₂; X = N; Z = O; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using phenoxazine (146 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[3,2-*d*]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 31: 9-[(2,4-Diaminoquinazolin-6-yl)methyl]phenoxazine (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; W = CH₂; X = N; Z = O; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using phenoxazine (146 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylquinazoline hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 32: 9-[(2,4-Diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]phenoxazine (Formula I: Ar = 2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl; W = CH₂; X = N; Z = O; m = n = 0) is prepared similarly to N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed in Example 11 above by using 2,4-diamino-5-methylthieno[2,3-*d*]pyrimidine (1.3 g, 7.4 mmol) in Step 1 and phenoxazine (146 mg, 0.8 mmol) in Step 3. The final product and its intermediates can be purified by chromatography.

- 28 -

Example 33: 9-[(2,4-Diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]phenoxazine (Formula I: Ar = 2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl; W = CH₂; X = N; Z = O; m = n = 0) is prepared similarly to N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed in Example 11 above by using phenoxazine (146 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-chloromethylfuro[2,3-*d*]pyrimidine (60 mg, 0.3 mmol). The product can be purified by chromatography.

Example 34: 9-[(2,4-Diaminopyrimidin-6-yl)methyl]phenoxazine (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH₂; X = N; Z = O; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using phenoxazine (146 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-bromomethylpyridine hydrobromide (86 mg, 0.3 mmol). The product can be purified by chromatography.

Example 35: N-[(2,4-Diaminopteridin-6-yl)methyl]phenothiazine (Formula I: Ar = 2,4-diaminopteridin-6-yl; W = CH₂; X = N; Z = S; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using phenothiazine (159 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpteridine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 36: 9-[(2,4-Diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]phenothiazine (Formula I: Ar = 2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl; W = CH₂; X = N; Z = S; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by starting from phenothiazine (159 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[2,3-*d*]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 37: 9-[(2,4-Diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]phenothiazine (Formula I: Ar = 2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl; W = CH₂; X = N; Z = S; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using phenothiazine (159 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[3,2-

- 29 -

d]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 38: 9-[(2,4-Diaminoquinazolin-6-yl)methyl]phenothiazine (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; W = CH₂; X = N; Z = S; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using phenothiazine (159 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylquinazoline hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 39: 9-[(2,4-Diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]phenothiazine (Formula I: Ar = 2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl; W = CH₂; X = N; Z = S; m = n = 0) is prepared similarly to N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed in Example 11 above by using 2,4-diamino-5-methylthieno[2,3-*d*]pyrimidine (1.3 g, 7.4 mmol) in Step 1 and phenothiazine (159 mg, 0.8 mmol) in Step 3. The final product and its intermediates can be purified by chromatography.

Example 40: 9-[(2,4-Diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]phenothiazine (Formula I: Ar = 2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl; W = CH₂; X = N; Z = S; m = n = 0) is prepared similarly to N-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed above by using phenothiazine (159 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-chloromethylfuro[2,3-*d*]pyrimidine (60 mg, 0.3 mmol). The product can be purified by chromatography.

Example 41: 9-[(2,4-Diaminopyrimidin-5-yl)methyl]phenothiazine (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH₂; X = N; Z = S; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using phenothiazine (159 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-bromomethylpyridine hydrobromide (86 mg, 0.3 mmol). The product can be purified by chromatography.

Example 42: N-[(2,4-Diaminopteridin-6-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine (Formula I: Ar = 2,4-diaminopteridin-6-yl; W = CH₂; X

- 30 -

= N; Z = CH₂CH₂; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10-dihydrodibenz[*b,f*]azepine (158 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpteridine hydrobromide (100 mg, 0.3 mmol). The product
5 can be purified by chromatography.

Example 43: 9-[(2,4-Diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]-9,10-dihydrodibenz-*[b,f]*azepine (Formula I: Ar = 2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl; W = CH₂; X = N; Z = CH₂CH₂; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10-
10 dihydrodibenz[*b,f*]azepine (158 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol) and 2,4-diamino-6-bromomethylpyrido[2,3-*d*]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 44: 9-[(2,4-Diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]-9,10-dihydrodibenz-*[b,f]*azepine (Formula I: Ar = 2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl; W = CH₂; X = N; Z = CH₂CH₂; m = n = 0) is prepared similarly to N-[(2,4-
15 diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10-dihydrodibenz[*b,f*]azepine (158 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[3,2-*d*]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 45: 9-[(2,4-Diaminoquinazolin-6-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; W = CH₂; X = N; Z = CH₂CH₂; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10-
20 dihydrodibenz[*b,f*]azepine (158 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylquinazoline hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 46: 9-[(2,4-Diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-9,10-dihydrodibenz-*[b,f]*azepine (Formula I: Ar = 2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl; W = CH₂; X = N; Z = CH₂CH₂; m = n = 0) is prepared similarly to N-[(2,4-
30 diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed in

Example 11 above, by using 2,4-diamino-5-methylthieno[2,3-*d*]pyrimidine (1.3 g, 7.4 mmol) in Step 1 and 9,10-dihydrodibenz[*b,f*]azepine (158 mg, 0.8 mmol) in Step 3. The final product and its intermediates can be purified by chromatography.

Example 47: 9-[(2,4-Diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine (Formula I: Ar = 2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl; W = CH₂; X = N; Z = CH₂CH₂; m = n = 0) is prepared similarly to N-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10-dihydrodibenz[*b,f*]azepine (158 mg, 0.8 mmol), sodium hydride (50 mg, 2.1 mmol), and 2,4-diamino-5-chloromethylfuro[2,3-*d*]pyrimidine (60 mg, 0.3 mmol). The product can be purified by chromatography.

Example 48: 9-[(2,4-Diaminopyrimidin-5-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH₂; X = N; Z = CH=CH; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using 9,10-dihydrodibenz[*b,f*]azepine (158 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-bromomethylpyrimidine hydrobromide (86 mg, 0.3 mmol). The product can be purified by chromatography.

Example 49: N-[(2,4-Diaminopteridin-6-yl)methyl]dibenz[*b,f*]azepine (Formula I: Ar = 2,4-diaminopteridin-6-yl; W = CH₂; X = N; Z = CH=CH; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above, by using dibenz[*b,f*]azepine (154 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpteridine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 50: 9-[(2,4-Diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]dibenz[*b,f*]azepine (Formula I: Ar = 2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl; W = CH₂; X = N; Z = CH=CH; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using dibenz[*b,f*]azepine (154 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[2,3-*d*]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

- 32 -

Example 51: 9-[(2,4-Diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]dibenz[*b,f*]azepine (Formula I: Ar = 2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl; W = CH₂; X = N; Z = CH=CH; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using
5 dibenz[*b,f*]azepine (154 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylpyrido[3,2-*d*]pyrimidine hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 52: 9-[(2,4-Diaminoquinazolin-6-yl)methyl]dibenz[*b,f*]azepine (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; W = CH₂; X = N; Z = CH=CH; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine as disclosed above by using dibenz[*b,f*]azepine (154 mg, 0.8 mmol),
10 NaH (50 mg, 2.1 mmol), and 2,4-diamino-6-bromomethylquinazoline hydrobromide (100 mg, 0.3 mmol). The product can be purified by chromatography.

Example 53: 9-[(2,4-Diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]dibenz[*b,f*]azepine (Formula I: Ar = 2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl; W = CH₂; X = N; Z = CH=CH; m = n = 0) is prepared similarly to N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed above
15 by using 2,4-diamino-5-methylthieno[2,3-*d*]pyrimidine (1.3 g, 7.4 mmol) in Step 1 and dibenz[*b,f*]azepine (154 mg, 0.8 mmol) in Step 3. The final product and its
20 intermediates can be purified by chromatography.

Example 54: 9-[(2,4-Diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]benz[*b,f*]azepine (Formula I: Ar = 2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl; W = CH₂; X = N; Z = CH=CH; m = n = 0) is prepared similarly to N-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine as disclosed above by
25 using dibenz[*b,f*]azepine (154 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-chloromethylfuro[2,3-*d*]pyrimidine (60 mg, 0.3 mmol). The product can be purified by chromatography.

Example 55: 9-[(2,4-Diaminopyrimidin-6-yl)methyl]dibenz[*b,f*]azepine (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH₂; X = N; Z = CH=CH; m = n = 0) is prepared similarly to N-[(2,4-diaminopteridin-6-yl)methyl]-N,N-diphenylamine
30

- 33 -

as disclosed above by using dibenz[*b,f*]azepine (154 mg, 0.8 mmol), NaH (50 mg, 2.1 mmol), and 2,4-diamino-5-bromomethylpyrimidine hydrobromide (86 mg, 0.3 mmol). The product can be purified by chromatography.

Example 56: N-(2,4-Diaminopyrido[2,3-*d*]pyrimidin-6-yl)benzhydramine
5 (Formula I: Ar = 2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl; W = NH; X = CH; Z = non-linked hydrogens on each phenyl group; m = n = 0).

A solution of benzhydramine (366 mg, 2.0 mmol) and 2,4,6-triaminopyrido[2,3-*d*]pyrimidine (350 mg, 2.0 mmol) in a mixture of DMF (40 mL) and glacial AcOH (4 mL) is treated with BH₃·Et₃N (75 mg, 6.6 mmol), and the
10 mixture is stirred at room temperature overnight, then diluted with H₂O (20 mL) to decompose any unreacted reducing agent. The solvents are evaporated under reduced pressure, and the residue is purified on a silica gel column using 5-15% CHCl₃ in MeOH as the eluent. Pooling and evaporation of appropriate fractions yields the title compound, N-(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)benzhydramine.

Example 57: N-[(2,4-Diaminoquinazolin-6-yl)amino]benzhydramine
15 (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; W = NH; X = CH; Z = non-linked hydrogens on each phenyl group; m = n = 0) is prepared similarly to N-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]benzhydramine as disclosed above by using benzhydramine (366 mg, 2.0 mmol), 2,4,6-triaminoquinazoline (350 mg, 2.0
20 mmol), and BH₃·Et₃N (75 mg, 6.6 mmol). The product can be purified by chromatography.

Example 58: N-[(2,4-Diaminopyrimidin-5-yl)methyl]benzhydramine
(Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH₂NH; X = CH; Z = non-linked
hydrogens on each phenyl group; m = n = 0) is prepared similarly to N-(2,4-
25 diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]benzhydramine as disclosed above by using benzhydramine (366 mg, 2.0 mmol), 2,4-diamino-5-aminomethylpyrimidine (278 mg, 2.0 mmol), mg, 2 mmol), and BH₃·Et₃N (75 mg, 6.6 mmol). The product can be purified by chromatography.

- 34 -

Example 59: N-[(2,4-Diaminopyrimidin-5-yl)ethyl]benzhydramine
(Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH₂CH₂NH; X = CH; Z = non-linked hydrogens on each phenyl group; m = n = 0) is prepared similarly to N-(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]benzhydramine as disclosed above by
5 using benzhydramine (366 mg, 2.0 mmol), 2,4-diamino-5-(2-aminoethyl)pyrimidine (306mg, 2.0 mmol), mg, 2.0 mmol), and BH₃·Et₃N (75 mg, 6.6 mmol). The product can be purified by chromatography.

Example 60: 9-[N-(2,4-Diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]fluorene
(Formula I: Ar = 2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl; W = NH; X = CH; Z =
10 chemical bond; m = n = 0) is prepared similarly to N-(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]benzhydramine as disclosed above by using fluorenone (360 mg, 2.0 mmol), 2,4,6-triaminopyrido[2,3-*d*]pyrimidine (350 mg, 2.0 mmol), mg, 2.0 mmol), and BH₃·Et₃N (75 mg, 6.6 mmol). The product can be purified by chromatography.

Example 61: 9-[N-(2,4-Diaminoquinazolin-6-yl)amino]fluorene (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; W = NH; Z = CH; Z = chemical bond; m = n = 0) is prepared similarly to N-(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)amino]fluorene as disclosed above by using fluorenone (360 mg, 2.0 mmol), 2,4,6-triaminoquinazoline (350mg, 2.0 mmol), and BH₃·Et₃N (75 mg, 6.6 mmol). The product can be purified
15 by chromatography.

Example 62: 9-[N-(2,4-Diaminopyrimidin-5-yl)methylamino]fluorene
(Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH₂NH is prepared similarly to N-(2,4-diaminopyrido-[2,3-*d*]pyrimidin-6-yl)amino]fluorene as disclosed above by
using fluorenone (360 mg, 2.0 mmol), 2,4-diamino-5-aminomethylpyrimidine (278
25 mg, 2.0 mmol), and BH₃·Et₃N (75 mg, 6.6 mmol). The product can be purified by chromatography.

Example 63: 9-[N-[2-(2,4-Diaminopyrimidin-5-yl)ethyl]amino]fluorene
(Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH₂CH₂NH; X = CH; Z = chemical bond; m = n = 0) is prepared similarly to N-(2,4-diaminopyrido[2,3-

- 35 -

d]pyrimidin-6-yl)amino]fluorene as disclosed above by using fluorenone (360 mg, 2.0 mmol), 2,4-diamino-5-(2-aminoethyl)pyrimidine (306 mg, 2.0 mmol), and $\text{BH}_3 \cdot \text{Et}_3\text{N}$ (75 mg, 6.6 mmol). The product can be purified by chromatography.

Example 64: 5-[N-(2,4-Diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]-5*H*-
10,11-dihydro-dibenzo[*a,d*]cycloheptene (Formula I: Ar = 2,4-diaminopyrido[2,3-
d]pyrimidin-6-yl; W = NH; X = CH; Z = CH_2CH_2 ; m = n = 0) is prepared similarly
to N-(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]fluorene as disclosed above by
using 5*H*-dibenzo[*a,d*]cycloheptene-5-one (416 mg, 2.0 mmol), 2,4,6-
triaminopyrido[2,3-*d*]pyrimidine (350 mg, 2.0 mmol), and $\text{BH}_3 \cdot \text{Et}_3\text{N}$ (75 mg, 6.6
mmol). The product can be purified by chromatography.

Example 65: 5-[N-(2,4-Diaminoquinazolin-6-yl)amino]-5*H*-10,11-
dihydrodibenzo[*a,d*]-cycloheptene (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; W =
NH; X = CH; Z = CH_2CH_2 ; m = n = 0) is prepared similarly to N-(2,4-
diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]fluorene as disclosed above by using 5*H*-
dibenzo[*a,d*]cycloheptane-5-one (416 mg, 2.0 mmol), 2,4,6-triaminoquinazoline (350
mg, 2.0 mmol), and $\text{BH}_3 \cdot \text{Et}_3\text{N}$ (75 mg, 6.6 mmol). The product can be purified by
chromatography.

Example 66: 5-[N-(2,4-Diaminopyrimidin-5-yl)methylamino]-5*H*-10,11-
dihydro-dibenzo[*a,d*]heptene (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W =
 CH_2NH ; Z = CH_2CH_2 ; m = n = 0) is prepared similarly to N-(2,4-diaminopyrido[2,3-
d]pyrimidin-6-yl)amino]fluorene as disclosed above by using 5*H*-
dibenzo[*a,d*]cycloheptan-5-one (416 mg, 2.0 mmol), 2,4-diamino-5-
aminomethylpyrimidine (278 mg, 2.0 mmol), and $\text{BH}_3 \cdot \text{Et}_3\text{N}$ (75 mg, 6.6 mmol). The
product can be purified by chromatography.

Example 67: 5-[N-[2-(2,4-Diaminopyrimidin-5-yl)ethyl]amino]-5*H*-10,11-
dihydro-dibenzo[*a,d*]cycloheptene (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W =
 $\text{CH}_2\text{CH}_2\text{NH}$; X = CH; Z = $\text{CH}=\text{CH}$; m = n = 0) is prepared similarly to N-(2,4-
diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]fluorene as disclosed above by using 5*H*-
dibenzo[*a,d*]cycloheptan-5-one (416 mg, 2.0 mmol), 2,4-diamino-5-(2-

- 36 -

aminoethyl)pyrimidine (306 mg, 2.0 mmol), and $\text{BH}_3 \cdot \text{Et}_3\text{N}$ (75 mg, 6.6 mmol). The product can be purified by chromatography.

Example 68: 5-[N-(2,4-Diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]-5*H*-dibenzo[*a,d*]-cycloheptene (Formula I: Ar = 2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl; W = NH; X = CH; Z = CH=CH; m = n = 0) is prepared similarly to N-(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]fluorene as disclosed above by using 5*H*-dibenzo[*a,d*]cycloheptan-5-one (412 mg, 2.0 mmol), 2,4,6-triaminopyrido[2,3-*d*]pyrimidine (350 mg, 2.0 mmol), and $\text{BH}_3 \cdot \text{Et}_3\text{N}$ (75 mg, 6.6 mmol). The product can be purified by chromatography.

Example 69: 5-[N-(2,4-Diaminoquinazolin-6-yl)amino]-5*H*-dibenzo[*a,d*]cycloheptene (Formula I: Ar = 2,4-diaminoquinazolin-6-yl; W = NH; X = CH; Z = CH=CH; m = n = 0) is prepared similarly to N-(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]fluorene as disclosed above by using 5*H*-dibenzo[*a,d*]cycloheptan-5-one (412 mg, 2.0 mmol), 2,4,6-triaminoquinazoline (350 mg, 2.0 mmol), and $\text{BH}_3 \cdot \text{Et}_3\text{N}$ (75 mg, 6.6 mmol). The product can be purified by chromatography.

Example 70: 5-[N-(2,4-Diaminopyrimidin-5-yl)methylamino]-5*H*-dibenzo[*a,d*]heptene (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = CH_2NH ; X = CH; Z = chemical bond; m = n = 0) is prepared similarly to N-(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]fluorene as disclosed above by using 5*H*-dibenzo[*a,d*]cycloheptan-5-one (412 mg, 2.0 mmol), 2,4-diamino-5-aminomethylpyrimidine (278 mg, 2.0 mmol), and $\text{BH}_3 \cdot \text{Et}_3\text{N}$ (75 mg, 6.6 mmol). The product can be purified by chromatography.

Example 71: 5-[N-[2-(2,4-Diaminopyrimidin-5-yl)ethyl]amino]-5*H*-dibenzo[*a,d*]heptene (Formula I: Ar = 2,4-diaminopyrimidin-5-yl; W = $\text{CH}_2\text{CH}_2\text{NH}$; X = CH=CH; m = n = 0) is prepared similarly to N-(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]fluorene as disclosed above by using 5*H*-dibenzo[*a,d*]cycloheptan-5-one (412 mg, 2.0 mmol), 2,4-diamino-5-(2-

- 37 -


aminoethyl)pyrimidine (306 mg, 2.0 mmol), and $\text{BH}_3 \cdot \text{Et}_3\text{N}$ (75 mg, 6.6 mmol). The product can be purified by chromatography.

Example 72: Dihydrofolate reductase inhibition

Compounds of the invention were tested for inhibition of dihydrofolate reductase (DHFR) from rat liver, *Pneumocystis carinii* and *Toxoplasmosis gondii*. IC_{50} values were determined, which is the concentration (:M) of a compound required to inhibit the dihydrofolate reductase activity by 50%. Selectivity ratios are also set forth in the table. The DHFR inhibition assay was conducted by the procedures disclosed in Broughton, M.C. et al., *Antimicrob. Agents Chemother.*, 1991, 35: 1348-1355; Chio, L.C. et al., *Antimicrob. Agents Chemother.*, 1993, 37: 1914-1923. Results are set forth in Table 1 below, with the tested compound identified by reference to the structural formula set forth at the top of the table.

- 38 -

Table 1. Inhibition of *Pneumocystis carinii*, *Toxoplasma gondii*, and rat liver dihydrofolate reductase by compounds of the invention.



cmpd	X	DHFR inhibition (IC ₅₀ μM) ^c			selectivity ratio	
		<i>P. carinii</i>	<i>T. gondii</i>	rat liver	rat liver/ <i>P. carinii</i>	rat liver/ <i>T. gondii</i> liver
1	a	4.9	1.3	2.8	0.57	2.2
2	b	0.10	0.055	0.012	0.55	0.022
3	CH ₂	0.042	0.029	0.027	0.64	0.93
4	O	3.4	2.2	13	3.8	5.9
5	S	0.12	0.11	0.20	1.7	1.8
6 ^c	CH ₂ CH ₂	expt 1	1.7	0.89	4.4	
		expt 2	1.0	0.93	2.7	
		mean	1.4	0.91	5.1	
7 ^c	CH=CH	expt 1	0.24	0.010	2.1	
		expt 2	0.18	0.041	9.3	
		expt 3		0.084	4.4	
		mean	0.21	0.045	5.3	
					25	118

^a No bridge between the phenyl rings (i.e. X is non-linked hydrogens)

^b Direct bridge between the phenyl rings (i.e. X is a chemical bond)

^c Replicate assays performed on different days

- 39 -

Example 73: Additional data of N-[2,4-diaminopteridin-6-yl)methyldibenz
[b,f]azepine

It was also found that N-[2,4-diaminopteridin-6-yl)methyldibenz[b,f]azepine inhibited the proliferation of *T. gondii* cells in culture as measured by a standard assay based on [³H]uracil incorporation into the acid-insoluble fraction. The assay protocol is disclosed in Chio, L.C. et al., *Antimicrob. Agents Chemother.*, 1993, 37: 1914-1923. Incorporation relative to untreated controls was inhibited by 90% at a concentration of N-[2,4-diaminopteridin-6-yl)methyldibenz[b,f]azepine of 1 micromolar and the IC₅₀ was about 0.3 micromolar. A typical IC₅₀ for current antixoplasmosis clinic agent pyrimethamine in this assay is 0.5-0.8 micromolar. It thus appears that N-[2,4-diaminopteridin-6-yl)methyldibenz[b,f]azepine is at least as active as pyrimethamine in this assay.

The ratio IC₅₀(uracil incorporation)/IC₅₀ (DHFR inhibition) can indicate the efficiency of drug uptake by a parasite. In the case of the clinical agent pyrimethamine, this ratio is about 1.7. In the case of N-[2,4-diaminopteridin-6-yl)methyldibenz[b,f]azepine, whose IC₅₀ (DHFR inhibition) is 0.045 micromolar and whose IC₅₀ (uracil incorporation) is about 0.3 micromolar, the ratio calculated from these data is 6.7. That indicates that the uptake of N-[2,4-diaminopteridin-6-yl)methyldibenz[b,f]azepine is about four times more efficient than that of pyrimethamine.


N-[2,4-diaminopteridin-6-yl)methyldibenz[b,f]azepine is also active against intact *P. carinii* cells as measured by a different assay based on incorporation of [³H]para-aminobenzoic acid (PABA) into the total cellular folate pool of freshly harvested cells from a rat. The assay protocol that was employed is described in Kovacs, J.A., et al., *J. Infect. Dis.*, 1989, 160: 312-320; and Chio, L.C. et al., *Antimicrob. Agents Chemother.*, 1993, 37: 1914-1923. This assay can be used as measure of cell viability after drug treatment, and relies on the fact that *P. carinii* do not take up exogenous folates but can make their own folates de novo from PABA. After 5 hours of treatment with 17.6 micromolar N-[2,4-diaminopteridin-6-yl)methyldibenz[b,f]azepine there was about a 60% decrease in uptake of [³H]PABA

- 40 -

relative to controls. From this data, it can be estimated that the growth inhibitory concentration of N-[2,4-diaminopteridin-6-yl)methyldibenz[*b,f*]azepine against *P. carinii* in an established culture is about 10 micromolar or less depending on the length of treatment.

Example 74: Inhibition of dihydrofolate reductase (DHFR) from *Mycobacterium avium*

Compounds of the invention were tested for inhibition of dihydrofolate reductase (DHFR) from *Mycobacterium avium* (*M. avium*), an organism which has been used to screen drug candidates for activity against tuberculosis. IC₅₀ values were determined, which is the concentration (:M) of a compound required to inhibit the specified dihydrofolate reductase activity by 50%. Selectivity ratios also were determined and set forth in the table, which are calculated as the ratio of IC₅₀ rat liver to IC₅₀ *M. avium*. The DHFR inhibition assay was conducted by the procedures disclosed in Broughton, M.C. et al., *Antimicrob. Agents Chemother.*, 1991, 35: 1348-1355; Chio, L.C. et al., *Antimicrob. Agents Chemother.*, 1993, 37: 1914-1923. Results are set forth in Table 2 below, with the tested compound identified by reference to the structural formula set forth at the top of the table (substituent X specified in Table 2), IC₅₀ values (expressed in :M) against rat liver DHFR and *M. avium* DHFR, followed by the selectivity index.

Table 2. Inhibition of dihydrofolate reductase from *Mycobacterium avium*

Cmpd	X	rat liver DHFR	<i>M. avium</i> DHFR	Selectivity Index
1	CH=CH	2.1	0.012	175
2	^a	4.0	3.7	1.1
3	CH ₂	0.027	0.017	1.6
4	O	13	2.5	5.2
5	S	0.20	0.029	6.9


^a No bridge between the phenyl rings (i.e. X is non-linked hydrogens)

The invention has been described in detail with reference to preferred embodiments thereof. However, it will be appreciated that those skilled in the art, upon consideration of this disclosure, may make modifications and improvements within the spirit and scope of the invention as set forth in the following claims.

- 42 -

What is claimed is:

1. A compound of the following Formula I:



wherein Ar is optionally substituted carbocyclic aryl or optionally substituted heteroaromatic;

W is a chemical bond, optionally substituted amino, optionally substituted alkylene having 1 to about 3 carbon atoms, or aminoalkylene having 1 nitrogen and 1 or 2 carbon atoms;

X is nitrogen or carbon;


Z represents a chemical bond, optionally substituted methylene, optionally substituted ethylene, optionally substituted vinyl, optionally substituted azamethinyl, optionally substituted azamethylene, O, S, or optionally substituted N, or Z represents non-linked substituents on each phenyl group;

each R^1 and R^2 independently may be halogen, amino, hydroxy, nitro, azido, optionally substituted alkyl preferably, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted alkanoyl, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted carbocyclic aryl, or optionally substituted heteroaromatic, or optionally substituted heteroalicyclic;

m and n are each independently an integer of from 0 to 4; and
pharmaceutically acceptable salts thereof.

- 43 -

2. A compound of the following Formula IA:



wherein Ar is optionally substituted carbocyclic aryl or optionally substituted heteroaromatic;

W is a chemical bond, optionally substituted amino, optionally substituted alkylene having 1 to about 3 carbon atoms, or aminoalkylene having 1 nitrogen and 1 or 2 carbon atoms;

X is nitrogen or carbon;


Z represents a chemical bond, optionally substituted methylene, optionally substituted ethylene, optionally substituted vinyl, optionally substituted azamethinyl, optionally substituted azamethylene, O, S, or optionally substituted N, or Z represents non-linked substituents on each phenyl group;

each R¹ and R² independently may be halogen, amino, hydroxy, nitro, azido, optionally substituted alkyl preferably, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted alkanoyl, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted carbocyclic aryl, or optionally substituted heteroaromatic, or optionally substituted heteroalicyclic;

m and n are each independently an integer of from 0 to 5; and pharmaceutically acceptable salts thereof.

3. A compound of the following Formula II:

- 44 -



wherein Ar is optionally substituted carbocyclic aryl or optionally substituted heteroaromatic;


Z represents a chemical bond, optionally substituted methylene, optionally substituted ethylene, optionally substituted vinyl, optionally substituted azamethinyl, optionally substituted azamethylene, O, S, or optionally substituted N, or Z represents non-linked substituents on each phenyl group;

X is nitrogen or carbon;

each R^1 and R^2 independently may be halogen, amino, hydroxy, nitro, azido, optionally substituted alkyl preferably, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted alkanoyl, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted carbocyclic aryl, or optionally substituted heteroaromatic, or optionally substituted heteroalicyclic;

m and n are each independently an integer of from 0 to 4; and pharmaceutically acceptable salts thereof.

4. A compound of the following Formula IIA:



wherein Ar is optionally substituted carbocyclic aryl or optionally substituted heteroaromatic;


Z represents a chemical bond, optionally substituted methylene, optionally substituted ethylene, optionally substituted vinyl, optionally substituted azamethinyl, optionally substituted azamethylene, O, S, or optionally substituted N, or Z represents non-linked substituents on each phenyl group;

X is nitrogen or carbon;

each R^1 and R^2 independently may be halogen, amino, hydroxy, nitro, azido, optionally substituted alkyl preferably, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted alkanoyl, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted carbocyclic aryl, or optionally substituted heteroaromatic, or optionally substituted heteroalicyclic;

m and n are each independently an integer of from 0 to 4; and pharmaceutically acceptable salts thereof.

5. A compound of the following Formula III:



T, U and V are each independently optionally substituted carbon, or optionally substituted nitrogen;

- 46 -

W is a chemical bond, optionally substituted amino, optionally substituted alkylene having 1 to about 3 carbon atoms, or aminoalkylene having 1 nitrogen and 1 or 2 carbon atoms;


X is nitrogen or carbon;

Z represents a chemical bond, optionally substituted methylene, optionally substituted ethylene, optionally substituted vinyl, optionally substituted azamethinyl, optionally substituted azamethylene, O, S, or optionally substituted N, or Z represents non-linked substituents on each phenyl group;

each R^1 , R^2 and R^3 independently may be halogen, amino, hydroxy, nitro, azido, optionally substituted alkyl preferably, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted alkanoyl, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted carbocyclic aryl, or optionally substituted heteroaromatic, or optionally substituted heteroalicyclic;

m and n are each independently an integer of from 0 to 4; o is an integer of from 0 to 5 and pharmaceutically acceptable salts thereof.

6. A compound of the following Formula IV:



U and V are each independently optionally substituted carbon, or optionally substituted nitrogen;

- 47 -

W is a chemical bond, optionally substituted amino, optionally substituted alkylene having 1 to about 3 carbon atoms, or aminoalkylene having 1 nitrogen and 1 or 2 carbon atoms;


X is nitrogen or carbon;

Z represents a chemical bond, optionally substituted methylene, optionally substituted ethylene, optionally substituted vinyl, optionally substituted azamethinyl, optionally substituted azamethylene, O, S, or optionally substituted N, or Z represents non-linked substituents on each phenyl group;

each R^1 and R^2 independently may be halogen, amino, hydroxy, nitro, azido, optionally substituted alkyl preferably, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted alkanoyl, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted carbocyclic aryl, or optionally substituted heteroaromatic, or optionally substituted heteroalicyclic;

m and n are each independently an integer of from 0 to 4; and pharmaceutically acceptable salts thereof.

7. A compound of the following Formula IVA:



U and V are each independently optionally substituted carbon, or optionally substituted nitrogen;

- 48 -

W is a chemical bond, optionally substituted amino, optionally substituted alkylene having 1 to about 3 carbon atoms, or aminoalkylene having 1 nitrogen and 1 or 2 carbon atoms;

X is nitrogen or carbon;

Z represents a chemical bond, optionally substituted methylene, optionally substituted ethylene, optionally substituted vinyl, optionally substituted azamethinyl, optionally substituted azamethylene, O, S, or optionally substituted N, or Z represents non-linked substituents on each phenyl group;

each R¹ and R² independently may be halogen, amino, hydroxy, nitro, azido, optionally substituted alkyl preferably, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aminoalkyl, optionally substituted alkanoyl, optionally substituted alkylthio, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted carbocyclic aryl, or optionally substituted heteroaromatic, or optionally substituted heteroalicyclic;

m and n are each independently an integer of from 0 to 4; and pharmaceutically acceptable salts thereof.

8. A compound of any one of claims 1, 3, 4, 5, 6 or 7 wherein Z is -CH₂-, -CH₂CH₂-, NH, O, or S.

9. A compound of any one of claims 1, 2, 5, 6 or 7 wherein W is a bond, CH₂, CH₂CH₂, or NH.

10. A compound of claim 1 wherein the compound is:

N-(2,4-diaminopteridin-6-yl)methyl-N,N-diphenylamine;

2,4-diamino-6-(carbazol-5-yl)methylpteridine;

2,4-diamino-6-(9,10-dihydroacridin-9-yl)methylpteridine;

N-[(2,4-diaminopteridin-6-yl)methyl]phenoxazine;

N-[(2,4-diaminopteridin-6-yl)methyl]phenothiazine;

- 49 -

N-[(2,4-diaminopteridin-6-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine;
N-[(2,4-diaminopteridin-6-yl)methyl]dibenz[*b,f*]azepine;
N-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]-N,N-diphenylamine;
N-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]-N,N-diphenylamine;
N-[(2,4-diaminoquinazolin-6-yl)methyl]-N,N-diphenylamine;
N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine;
N-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]-N,N-diphenylamine;
N-[(2,4-diaminopyrimidin-6-yl)methyl]-N,N-diphenylamine;
N-[(2,4-diaminopteridin-6-yl)methyl]carbazole;
N-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]carbazole;
N-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]carbazole;
N-[(2,4-diaminoquinazolin-6-yl)methyl]carbazole;
N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]carbazole;
N-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]carbazole;
N-[(2,4-diaminopyrimidin-6-yl)methyl]carbazole;
N-[(2,4-diaminopteridin-6-yl)methyl]-9,10-dihydroacridine;
N-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]-9,10-dihydroacridine;
N-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]-9,10-dihydroacridine;
N-[(2,4-diaminoquinazolin-6-yl)methyl]-9,10-dihydroacridine;
N-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-9,10-dihydroacridine;
N-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]-9,10-dihydroacridine;
N-[(2,4-diaminopyrimidin-6-yl)methyl]-9,10-dihydroacridine;
N-[(2,4-diaminopteridin-6-yl)methyl]phenoxazine;

9-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]phenoxazine;
9-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]phenoxazine;
9-[(2,4-diaminoquinazolin-6-yl)methyl]phenoxazine;
9-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]phenoxazine;
9-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]phenoxazine;
9-[(2,4-diaminopyrimidin-6-yl)methyl]phenoxazine;
N-[(2,4-diaminopteridin-6-yl)methyl]phenothiazine;
9-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]phenothiazine;
9-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]phenothiazine;
9-[(2,4-diaminoquinazolin-6-yl)methyl]phenothiazine;
9-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]phenothiazine;
9-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]phenothiazine;
9-[(2,4-diaminopyrimidin-5-yl)methyl]phenothiazine;
N-[(2,4-diaminopteridin-6-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine;
N-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine;
N-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine;
9-[(2,4-diaminoquinazolin-6-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine;
9-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine;
9-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine;
9-[(2,4-diaminopyrimidin-5-yl)methyl]-9,10-dihydrodibenz[*b,f*]azepine;
N-[(2,4-diaminopteridin-6-yl)methyl]dibenz[*b,f*]azepine;
9-[(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)methyl]dibenz[*b,f*]azepine;
9-[(2,4-diaminopyrido[3,2-*d*]pyrimidin-6-yl)methyl]dibenz[*b,f*]azepine;

- 51 -

9-[(2,4-diaminoquinazolin-6-yl) methyl]dibenz[*b,f*]azepine;
9-[(2,4-diaminothieno[2,3-*d*]pyrimidin-5-yl)methyl]dibenz[*b,f*]azepine;
9-[(2,4-diaminofuro[2,3-*d*]pyrimidin-5-yl)methyl]dibenz[*b,f*]azepine;
9-[(2,4-diaminopyrimidin-6-yl)methyl]dibenz[*b,f*]azepine;
N-(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)benzhydramine;
N-(2,4-diaminoquinazolin-6-yl)benzhydramine;
N-[(2,4-diaminopyrimidin-5-yl)methyl]benzhydramine;
N-[(2,4-diaminopyrimidin-5-yl)ethyl]benzhydramine;
9-[N-(2,4-diaminoquinazolin-6-yl)amino]fluorene;
9-[N-(2,4-diaminoquinazolin-5-yl)methylamino]fluorene;
9-[N-[2-(2,4-diaminoquinazolin-5-yl)ethyl]amino]fluorene;
5-[N-(2,4-diaminopyrido[2,3-*d*]pyrimidin-6-yl)amino]-5*H*-10,11-dihydro-
dibenzo[*a,d*]cycloheptene;
5-[N-(2,4-diaminoquinazolin-6-yl)amino]-5*H*-10,11-
dihydrodibenzo[*a,d*]cycloheptene;
5-[N-(2,4-diaminopyrimidin-5-yl)methylamino]-5*H*-10,11-dihydrodibenzo
[*a,d*]cycloheptene;
5-[N-[2-(2,4-diaminopyrimidin-5-yl)ethyl]amino]-5*H*-10,11-dihydrodibenzo
[*a,d*]cycloheptene;
5-[N-(2,4-diaminopyrimidin-[2,3-*d*]pyrimidin-6-yl)amino]-5*H*-dibenzo
[*a,d*]cycloheptene;
5-[N-(2,4-diaminoquinazolin-6-yl)amino]-5*H*-dibenzo [*a,d*]cycloheptene;
5-[N-(2,4-diaminopyrimidin-5-yl)methylamino]-5*H*-dibenzo[*a,d*]cycloheptene; and
5-[N-[2-(2,4-diaminopyrimidin-5-yl)ethyl]amino]-5*H*-dibenzo[*a,d*]cycloheptene; and
pharmaceutically acceptable salts thereof.

- 52 -

11. A method of treating a patient suffering from or susceptible to a parasitic disease, comprising administering to the patient an effective amount of a compound of any one of claim 1-10.
12. A method of treating a patient suffering from or susceptible to toxoplasmosis, comprising administering to the patient an effective amount of a compound of any one of claim 1-10.
13. The method of claim 11 or 12 wherein the patient's immune system is suppressed.
14. The method of claim 11 or 12 wherein the patient has a retrovirus infection.
15. The method of claim 11 or 12 wherein the patient has an HIV infection.
16. The method of claim 11 or 12 wherein the patient is suffering from AIDS.
17. The method of claim 11 or 12 wherein the patient has received or will be receiving immunosuppressive cancer chemotherapy treatment.
18. A method of treating a patient suffering from or susceptible to cryptosporidiosis, leishmaniasis or malaria, comprising administering to the patient an effective amount of a compound of any one of claims 1-10.
19. A method of treating a patient suffering from or susceptible to an infection of *Toxoplasma gondii*, *Pneumocystis carinii*, *Cryptosporidium*, *Leishmania*, *Plasmodium vivax*, *P. falciparum*, *P. malarie*, or *P. ovale*.
20. A method of treating a patient suffering from or susceptible to a *Toxoplasma gondii* infection.
21. A method of treating a patient suffering from or susceptible to tuberculosis.
22. A method of any one of claims 11-21 wherein the disease is treated without administration of a sulfa drug to the patient.

- 53 -

23. The method of any one of claims 11-22 wherein the patient is a mammal.
24. A method of any one of claims 11-22 wherein the patient is a human.
25. A method of claim 11, 12 or 20 wherein the patient is a livestock animal, poultry or a domesticated animal.
26. A pharmaceutical composition a pharmaceutically acceptable carrier and a compound of any one of claims 1-10.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/01968

A. CLASSIFICATION OF SUBJECT MATTER			
IPC(7) : C07D 209/82, 403/04, 403/06, 403/12, 473/16, 475/08			
US CL : 544/260, 284, 297; 546/276.7; 548/440, 444, 445			
According to International Patent Classification (IPC) or to both national classification and IPC			
B. FIELDS SEARCHED			
Minimum documentation searched (classification system followed by classification symbols) U.S. : 544/260, 284, 297; 546/276.7; 548/440, 444, 445			
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched HURST's "Chemistry of the Pyrimidines, Purines, and Pteridines"			
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS ONLINE substructure search MEDLINE			
C. DOCUMENTS CONSIDERED TO BE RELEVANT			
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
X	SHAFI, S.S. ET AL. Studies on biochemically active heterocycles: part II. Synthesis of 2-(1,2,3,4-tetrahydro-9-carbazolylmethyl)thiazolo[3,2-b]-s-triazol-5(6H)-one and related systems. Indian J. Heterocycl. Chem., 1998, Vol. 7 No. 3, pages 231-232, especially compounds 1, 2, 4, and 5, SCHEME-1 and first column page 232.	1, 3, 9	
X, P	ROSOWSKY, A. ET AL. Structure-Based Design of Selective Inhibitors of Dihydrofolate Reductase: Synthesis and Antiparasitic Activity of 2,4-Diaminopteridine Analogues with a Bridged Diarylamine Side Chain. J. Med. Chem., 1999, Vol. 42 No. 23 pages 4853-4860, especially compound 4f, page 4858 (English) 1999	1, 3, 6, 9, and 10	
X	JP 06-135946 A2 (OTSUKA PHARMA CO. LTD.) 17 May 1994 (17.05.1994), compound 16 on page 18 and compound 24 on page 29	1, 3, 5, and 9	
X	KATRITZKY, A.R. ET AL. Chemistry of benzotriazole. Preparation, lithiation and transformation of N-(benzotriazol-1-ylmethyl) heterocycles. 1989, Vol. 26, No. 3, pages 829-36, especially compound 3 Scheme 1 and Tables 1 & 2 on page 830.	1, 3, and 9	
X	PRAGST, F. ET AL. Rearrangement of 1-amino-4-methylpyridinium ions into 4-aminomethylpyrimidines under the action of bases, Z. Chem., 1987, Vol. 27, No. 8, pages 289-90, especially compound 3c in Table 1 on page 290.	1, 3, 5, and 9	
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.			
* Special categories of cited documents:			
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier application or patent published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search 22 July 2000 (22.07.2000)		Date of mailing of the international search report 22 AUG 2000	
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230		Authorized officer Mukund Shah <i>Sella Collins for</i> Telephone No. (703) 308-1235	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/01968

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages -	Relevant to claim No.
X	FELDMAN, ET AL. Some Reactions of Methylene-bis-Amides as Amino-aldehydes. J. Org. Chem., January 1942, Vol. 7, pages 31-47, especially compound XXV, figure on page 37 and paragraphs 5(I)-5(II) spanning pages 44-45.	1, 3, and 6
X	LUGOVKIN, ET AL. J. ORGANIC Chem. USSR (Engl. Transl.), 1964, Vol. VII, pages 1124- especially compound IV figure on page 1124 and second paragraph on page 1126.	1, 3, and 9
X	GB 822,592A (CHEMISCHE FABRIK, PROMONTA, GMBH) 28 October 1959 (28.10.1959), page 2 line 52 to page 3 line 2, page 3 lines 81 to 106, page 4 lines 27 to 56, page 4, lines 93 to 121, page 5 lines 20 to 45, page 6 line 106 to page 7 line 3, page 7 lines 52 to 75, page 7 lines 100 to 125.	1, 3, 5, and 9
A	HURST, Derek T. Chemistry of the Pyrimidines, Purines, and Pteridines, London: John Wiley and Sons, 1980 especially Section (E) pages 168-171 and Section (C) pages 241-242	1, 3-7, 9, and 10

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/01968

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claim Nos.: 11-18 and 22-26
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1, 3-7, 9, and 10

Remark on Protest

☐
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/01968

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) parts of 1, 3-7, 9-10, drawn to Carbazoles.

Group II, claim(s) parts of 1, 3-7, 9-10 drawn to 9-substituted Acridines.

Group III, claim(s) parts of 1, 3-10, drawn to 5-substituted Dibenzazepines.

Group IV, claim(s) parts of 1, 3-7, 9, 11-10, drawn to 5-substituted Dibenzodiazepines.

Group V, claim(s) parts of 1, 3-10, drawn to Phenoxazines.

Group VI, claim(s) parts of 1, 3-10, drawn to Phenothiazines.

Group VII, claim(s) parts of 1, 3-9, 11-10, drawn to Phenazines.

Group VIII, claim(s) parts of 1, 3-10, drawn to all carbon tricyclic compounds.

Group IX, claim(s) parts of 1, 3-9, 11-10, drawn to 11-substituted Dibenzazepines.

Group X, claim(s) parts of 1, 3-9, 11-10, drawn to Dibenzopyrans.

Group XI, claim(s) parts of 1, 3-9, 11-10, drawn to Dibenzothiopyrans.

Group XII, claim(s) parts of 1, 3-7, 9, 11-10, drawn to 10-substituted Acridines.

Group XIII, claim(s) parts of 1-7, 9-10 drawn to N, N-Diphenylamines.

Group XIV, claim(s) parts of 1-7, 9, 11-10, drawn to Diphenylmethanes.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.